◆ 会议时间：2024年6月28日至7月2日
◆ 会议地点：美国 费城
◆ 会议简介：
2024年第21届儿童神经肿瘤学国际研讨会(ISPNO)将于2024年6月28日至7月2日在美国费城举行。
国际小儿神经肿瘤研讨会（ISPNO）每两年召开一次，是全球首屈一指的多学科全球性会议，旨在促进转化和临床研究与技术进步，是参与中枢神经系统肿瘤的科学研究，诊断，治疗，及婴幼儿、儿童和青少年患者康复治疗的专业人士交流学习的国际平台。自1986年在日本东京举办第一次会议以来，ISPNO与会人数一直保持稳定的增长。ISPNO2022议题几乎涵盖了儿科神经肿瘤学的所有方面，包括诊断、临床试验、新的治疗、基础和转化研究、神经放射学、心理学、生活质量、护理和患者治疗等等。ISPNO的与会者包括神经肿瘤学家、神经外科医生、放射肿瘤学家、基础和转化科学家、发育和普通儿科医生、神经学家、神经病理学家、神经放射学家、内分泌学家、康复专家、护士、心理学家、物理治疗师、职业治疗师和社会工作者等。未经本站许可禁止复制转载镜像本站任何内容—领域国际医学会议网(lingyuint.com)。
The 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024)
Date: June 28 – July 2, 2024
Venue: Philadelphia, PA, USA
摘要征文投稿：
Please click on the link below to submit your abstracts for the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024). The submission deadline is on Monday, February 5, 2024, at 11:59 PM ET. Abstracts submitted after the deadline will not be accepted.
All accepted abstracts will be published as submitted in an online supplement to Neuro-Oncology. Edits to abstracts cannot be made after the February 5, 2024, deadline. Abstract submitters should carefully check their abstract for content errors, spelling, names, etc. before submitting. ISPNO neither proofreads nor corrects spelling, typographical, grammatical, or scientific errors.
Once the accepted abstracts are submitted to the journal for publication, requests for withdrawals cannot be processed. Allrequeststowithdrawabstracts MUST bereceivedbyMonday,March11,2024,at11:59PMET.
All presenters are expected to register for the symposium and must be able to present in person. Pre-recorded or virtual presentation will not be allowed.
- Title – 50 word maximum
- Abstract – 300 word maximum
- Authors – maximum of 75 authors
- Institutional Affiliation – maximum of 2 per author
- Atypical Teratoid Rhabdoid Tumor
- Biological Correlates, Biomarkers
- Cancer Neuroscience
- Craniopharyngioma
- Diffuse Midline Glioma, Diffuse Intrinsic Pontine Glioma
- Diversity, Equity, and Inclusion
- Early Phase Clinical Trials/Developmental Therapeutics
- Embryonal Tumor with Multilayered Rosettes (ETMR), Other Embryonal Tumors, Rare tumors
- Ependymoma
- Epidemiology
- Genomics, Epigenomics, Metabolomics
- Germ Cell Tumors
- High Grade Glioma
- Imaging
- Immune-, Cell-, Gene-, and Viral-Based Therapies
- Low Grade Glioma
- Medulloblastoma
- Neurofibromatosis and other Cancer Predisposition Syndromes
- Neuropsychology, Quality of Life, Survivorship
- Neurosurgery, Drug Delivery
- Nursing, Social Work, Patient Support
- Others (not fitting any other category)
- Palliative Care
- Pathology, Classification
- Pediatric Neuro-Oncology in Low/Middle Income Countries
- Preclinical Models, Drug Discovery
- Radiation Oncology
- Tumor Biology, Stem Cells, Models
- Late Breaking (Please carefully read the guidelines below before submitting a late breaking abstract)
提交摘要：
Click here to submit your abstract or cut and paste this URL into a browser:
https://app.oxfordabstracts.com/stages/6898/submitter
Late Breaking Abstract Guidelines
ISPNO recognizes that some rapidly advancing investigations may include results that will not be available at the time of the abstract submission deadline of February 5, 2024. For this reason, ISPNO will allow authors to submit their Late-Breaking research for consideration for ISPNO, however submissions must adhere to guidelines below.
Please note that only a limited number of abstracts from this Late-Breaking category will be selected for oral presentation at the meeting. Authors should note the following important information before submitting a Late-Breaking Abstract:
- Late-Breaking abstracts will be considered for oral presentation only.
- Late-Breaking abstracts accepted for oral presentation will not be included in the regular abstract supplement to Neuro-Oncology and will be published electronically on the day of presentation.
- Late-Breaking abstracts not accepted for presentation will not be considered for any type of presentation format (poster or oral) and will not be part of the meeting program.
- Late-Breaking abstracts will not be considered for awards.
This category is not intended to offer a second deadline for regular abstract submissions.
For an abstract to be considered for Late-Breaking Abstract status, the submitting author must:
-
Select the “Late-Breaking Abstract” category in the abstract submission site.
-
Submit an abstract, including the objectives and methods but excluding the results and conclusions of the research, by the submission deadline of Monday, February 5, 2024. Include any information that supports the potential for late-breaking impact, and the date of planned analysis for the abstract.
- Submit a final Late-Breaking abstract (with updated data) by Monday, April 15, 2024. If an updated abstract is not submitted by that date, the abstract will be automatically rejected.
Dear Friends and Colleagues,
It is our great pleasure to invite you to the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024), which will take place in Philadelphia, PA, from June 28 – July 2, 2024.
The third ISPNO was held in 1991 in Philadelphia, and we are excited to host again! In the ensuing three decades, ISPNO has grown into the largest and most important scientific meeting focused on pediatric central nervous system tumors. It attracts clinicians and researchers from a wide range of disciplines including neuro-oncology, neurosurgery, radiation oncology, neurology, neuropathology, neuroradiology, neuropsychology, neuroscience, rehabilitation medicine, nursing, and more, as well as advocates and supporters of the pediatric neuro-oncology community. ISPNO welcomes attendees from around the world, including those joining for the first time. It is an amazing opportunity to meet experts in the field, learn about cutting-edge science, launch new collaborations, and catch up with colleagues and friends.
ISPNO 2024 will be hosted by the Children’s Hospital of Philadelphia Brain Tumor Program. The symposium will include a comprehensive scientific program covering the latest preclinical, translational, and clinical research updates on virtually all areas of pediatric neuro-oncology - diagnostics, treatment and clinical trial advances, novel drug delivery systems, biomarkers, preclinical models, tumor microenvironment, imaging, outcomes and late effects. There will also be an Education Day, nursing sessions, keynote lectures, panel discussions on challenging issues in the field, sunrise sessions, lunchtime symposia, and, of course, a social program.
As one of the largest cities in the United States, visitors to Philadelphia enjoy world-class restaurants, first rate museums, and beautiful city parks. In addition, as the birthplace of America, Philadelphia is steeped in historical significance with many extraordinary attractions like the Liberty Bell, Independence Hall, and the National Constitution Center. The symposium venue, the Philadelphia Marriott Downtown, is in the heart of the city (~15 minutes from the airport) and only a short walk to most of the historical sites and major city attractions. Philadelphia also provides easy access to other major U.S. cities, including New York and Washington, D.C. (both of which are only 1-2 hours by train), is one hour from the Atlantic Ocean, and is a great jumping off point for a vacation in the United States.
Please stay tuned for more information on ISPNO 2024 as the event approaches. We look forward to seeing you in Philadelphia!
Sincerely,
Michael J. Fisher, M.D.
Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Center for Childhood Cancer Research
and Division of Oncology
The Children’s Hospital of Philadelphia
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Phillip B. Storm, M.D.
Chief, Division of Neurosurgery
Co-Director, Neuroscience Center
Leslie N. Sutton Endowed Chair in Pediatric Neurosurgery
The Children’s Hospital of Philadelphia
Associate Professor of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
